Meet our partners
Global Partner
Takeda Ventures, Inc.
Takeda Ventures, Inc. is the corporate venture arm of Takeda Pharmaceutical Company, a world-class pharmaceutical company and the largest one in Japan, supporting therapeutic innovation in the biopharmaceutical sector through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company. Read more at takedaventures.com
News

Mar 2016 Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in United States

Mar 2016 Takeda Intends to Establish a Wholly Owned Subsidiary Operating in the Consumer Healthcare Business in Japan

Feb 2016 FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)


OneStart Europe Vision Film 2016

  • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Matthew Foy, Partner, SR One
  • Sarah Haywood, CEO, MedCity 
  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Lynne Murray, Partnering and Strategy, MedImmune
  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Stephen Reese, Partner, Olswang LLP 


From the OneStart London Bootcamp 2016

Panel Discussion

Panel Discussion: Investors


  • Matthew Foy, Partner, SROne (Chair)
  • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures Inc.
  • Deborah Harland, PhD, MBA, Partner, SROne
  • Nihal Sinha, MRCP, Senior Associate, F-Prime Capital Partners
  • Hasan Goker, PhD, Senior Investment Director, MS Ventures

From the OneStart San Francisco Bootcamp 2016

Panel Discussion

Panel Discussion: Investors

    • Matthew Foy, Partner, SR One (Chair)
    • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
    • Cayce Denton, VP, TPG Biotech 
    • Jenny Rooke, PhD, Manging Director, 5 Prime Ventures
    • Tracy Saxton, PhD, Investment Director, Roche Venture Fund


    From the OneStart London Bootcamp 2015

    Panel Discussion

    Panel Discussion: Case Studies from Life Science Companies

    • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC (Chair)
    • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
    • Chris Brown, MBA, Director, Scientific Licensing, Worldwide Business Development, GSK
    • Sarah Holland, DPhil(Oxon), MBA, Life Cycle Leader alectinib, Roche
    • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune


    Panel Discussion: Life Science & Healthcare Investors

    • Matthew Foy, Partner, SR One (Chair)
    • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
    • Maina Bhaman, Director of Healthcare Investments, Imperial Innovations
    • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC
    • Vishal Gulati, MD, Venture Partner, DFJ Esprit
    • Deborah Harland, PhD, MBA, Partner, SR One

    Mentors
    Ilan Zipkin
    Senior Investment Director at Takeda Ventures, Inc. + more
    I have been involved in biotechnology and pharmaceutical venture capital since 2000. Previously I was a Partner at the institutional venture firms Prospect Venture Partners and MPM Capital, where I focused on investments in therapeutics companies as well as platform technologies. In addition to serving on the Board of several private and public biotechnology companies, I served as the CEO of Chimeros, Inc., a protein-based system for the development of multivalent biologic therapeutics.
    Michal Silverberg
    Senior Director, External Innovation, Takeda Ventures + more
    Currently based in Israel, I joined TVI in September 2014 as Senior Director for External Innovation with a primary focus on Israel and Europe. Since 1998, I have held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies.
    Teams Mentored